glycine amide

02/01/1978 - "The writers present some physiological (and not therapeutic) acute and sub-acute trials with tripeptide: L-propyl-L-leucyl-glycine amide (M.I.F.-I) in Parkinson's Disease. "
12/09/1972 - "Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease."
01/01/1987 - "Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease."
08/01/1985 - "[Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease]."
04/15/2007 - "The neuropeptide melanocyte-inhibiting factor (MIF) or L-propyl-L-leucyl-glycinamide (PLG) has been reported in some studies to improve the motor signs of Parkinson's disease (PD) and in rodent models of PD. "

07/31/2020 - "The present study suggests that glycinamide hydrochloride has great potential to be used in the control of skin hyperpigmentation."
01/01/2019 - "Small peptides, including glycinamide and tryptophanyl glycinamide, are potent antimelanogenic agents with potential value for the treatment of skin hyperpigmentation."

04/29/2022 - "Among AA derivatives, MAP had a similar effect to AA in enhancing wound closure, and its effect was further enhanced by glycinamide. "
04/29/2022 - "The combination of AA and glycinamide synergistically enhanced collagen production and wound closure in HDFs to a level similar to that in cells treated with TGF-β1. "
12/01/2022 - "In this study, we designed a NAGA/GelMA/Laponite/glycerol hydrogel wound dressing that can release P-sEVs to accelerate angiogenesis and wound healing (named P-sEVs@hydrogel) (N-acryloyl glycinamide, NAGA). "

12/01/2005 - "The present study was undertaken to investigate the role of the hypothalamic tripeptide L-prolyl-L-leucyl-glycinamide (PLG) and its conformationally constrained analog 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) in modulating agonist binding to human dopamine (DA) receptor subtypes using human neuroblastoma SH-SY5Y cells stably transfected with respective cDNAs. "

04/01/2003 - "At present there are three compounds in clinical trials in patients with epilepsy that can be regarded as second-generation VPA: valproyl glycinamide, 3-methylbutanamide or isovaleramide and SPD421 (DP-VPA). "